TrialAnnals of the rheumatic diseases2017

Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial.

Daniel J Wallace et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.